125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report
The liver is the most common and lethal metastatic site in patients with extensive-stage small-cell lung cancer (ES-SCLC), and median survival with current standard treatment is only 9–10 months from diagnosis. Clinical observations show that a complete response (CR) is extremely rare in ES-SCLC pat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.965166/full |
| _version_ | 1827958903708581888 |
|---|---|
| author | Linlin Lu Yu Wang Lei Li Lan Yu Li Liu Baozhen Qu Xiaotao Zhang Xiaotao Zhang |
| author_facet | Linlin Lu Yu Wang Lei Li Lan Yu Li Liu Baozhen Qu Xiaotao Zhang Xiaotao Zhang |
| author_sort | Linlin Lu |
| collection | DOAJ |
| description | The liver is the most common and lethal metastatic site in patients with extensive-stage small-cell lung cancer (ES-SCLC), and median survival with current standard treatment is only 9–10 months from diagnosis. Clinical observations show that a complete response (CR) is extremely rare in ES-SCLC patients with liver metastasis. Moreover, to the best of our knowledge, complete regression of liver metastasis induced by the abscopal effect, boosted primarily by permanent radioactive iodine-125 seeds implantation (PRISI), combined with a low-dose metronomic temozolomide (TMZ) regimen, has not been recorded. Here, we present the case of a 54-year-old male patient who developed multiple liver metastases from ES-SCLC after multiple lines of chemotherapy. The patient was given partial PRISI therapy (two out of six tumor lesions; 38 iodine-125 seeds in one dorsal lesion and 26 seeds in one ventral lesion), which was combined with TMZ metronomic chemotherapy (50 mg/m2/day, days 1–21, every 28 days). The abscopal effect was observed for 1 month after PRISI treatment. After about 1 year, all the liver metastases had completely disappeared, and the patient experienced no relapse. The patient eventually died of malnutrition caused by a non-tumor intestinal obstruction and had an overall survival of 58.5 months after diagnosis. PRISI combined with TMZ metronomic chemotherapy might be considered a potential therapy to trigger the abscopal effect in patients with liver metastases. |
| first_indexed | 2024-04-09T15:44:21Z |
| format | Article |
| id | doaj.art-96b9d507b4b748819e0bc0563bd00c5c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T15:44:21Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-96b9d507b4b748819e0bc0563bd00c5c2023-04-27T05:32:52ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.965166965166125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case reportLinlin Lu0Yu Wang1Lei Li2Lan Yu3Li Liu4Baozhen Qu5Xiaotao Zhang6Xiaotao Zhang7Qingdao Cancer Prevention and Treatment Research Institute, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaDepartment of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaDepartment of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaDepartment of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaDepartment of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaQingdao Cancer Prevention and Treatment Research Institute, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaDepartment of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Qingdao, ChinaDepartment of Oncology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, ChinaThe liver is the most common and lethal metastatic site in patients with extensive-stage small-cell lung cancer (ES-SCLC), and median survival with current standard treatment is only 9–10 months from diagnosis. Clinical observations show that a complete response (CR) is extremely rare in ES-SCLC patients with liver metastasis. Moreover, to the best of our knowledge, complete regression of liver metastasis induced by the abscopal effect, boosted primarily by permanent radioactive iodine-125 seeds implantation (PRISI), combined with a low-dose metronomic temozolomide (TMZ) regimen, has not been recorded. Here, we present the case of a 54-year-old male patient who developed multiple liver metastases from ES-SCLC after multiple lines of chemotherapy. The patient was given partial PRISI therapy (two out of six tumor lesions; 38 iodine-125 seeds in one dorsal lesion and 26 seeds in one ventral lesion), which was combined with TMZ metronomic chemotherapy (50 mg/m2/day, days 1–21, every 28 days). The abscopal effect was observed for 1 month after PRISI treatment. After about 1 year, all the liver metastases had completely disappeared, and the patient experienced no relapse. The patient eventually died of malnutrition caused by a non-tumor intestinal obstruction and had an overall survival of 58.5 months after diagnosis. PRISI combined with TMZ metronomic chemotherapy might be considered a potential therapy to trigger the abscopal effect in patients with liver metastases.https://www.frontiersin.org/articles/10.3389/fonc.2023.965166/fullSCLCabscopal effectmetronomic chemotherapypermanent iodine-125 seeds implantationliver metastases |
| spellingShingle | Linlin Lu Yu Wang Lei Li Lan Yu Li Liu Baozhen Qu Xiaotao Zhang Xiaotao Zhang 125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report Frontiers in Oncology SCLC abscopal effect metronomic chemotherapy permanent iodine-125 seeds implantation liver metastases |
| title | 125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report |
| title_full | 125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report |
| title_fullStr | 125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report |
| title_full_unstemmed | 125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report |
| title_short | 125I Radiotherapy combined with metronomic chemotherapy may boost the abscopal effect, leading to complete regression of liver metastasis in an SCLC patient with a 58.5-month OS: a case report |
| title_sort | 125i radiotherapy combined with metronomic chemotherapy may boost the abscopal effect leading to complete regression of liver metastasis in an sclc patient with a 58 5 month os a case report |
| topic | SCLC abscopal effect metronomic chemotherapy permanent iodine-125 seeds implantation liver metastases |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.965166/full |
| work_keys_str_mv | AT linlinlu 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT yuwang 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT leili 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT lanyu 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT liliu 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT baozhenqu 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT xiaotaozhang 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport AT xiaotaozhang 125iradiotherapycombinedwithmetronomicchemotherapymayboosttheabscopaleffectleadingtocompleteregressionoflivermetastasisinansclcpatientwitha585monthosacasereport |